Re: Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy

Eur J Cancer. 2021 Sep:155:313-314. doi: 10.1016/j.ejca.2021.06.057. Epub 2021 Aug 6.

Authors

Kazuki Takada¹, Shinkichi Takamori², Naoko Miura¹, Yasunori Shikada¹, Mototsugu Shimokawa³

Affiliations

¹ Department of Surgery, Saiseikai Fukuoka General Hospital, 1-3-46 Tenjin, Chuo-ku, Fukuoka, Fukuoka 810-0001, Japan.
² Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, Fukuoka 811-1395, Japan. Electronic address: [email protected].
³ Department of Biostatistics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi 755-8505, Japan.

PMID: 34373189
DOI: 10.1016/j.ejca.2021.06.057

No abstract available

Publication types

Letter
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Immunologic Factors
Immunotherapy
Lung Neoplasms* / drug therapy
Pharmaceutical Preparations*

Substances

Immunologic Factors
Pharmaceutical Preparations